Elanco continues growth in animal nutrition market

Elanco, a global animal health company, is growing fast and plans to double revenue in five years.

The company's sales are growing at a rate faster than the overall animal health market, bolstered by recent acquisitions and the launch of its companion animal business. Year-to-date 2009 animal health sales exceeded US$850 million.

In 2010, Elanco is planning for seven new product launches and expanded indications, including two new companion animal products.

The company also aims to double revenue in five years with five strategic initiatives:

• Increased investment and industry leadership in innovation;
   
• Continued growth and increased presence in the companion animal business;
   
• Greater investment and focus on emerging market opportunities;
   
• Transforming its manufacturing cost structure to better support innovation growth and emerging market opportunities; and
   
• A further-enhanced business unit model to amplify "best in industry" employee engagement and focused execution.

With strategic investments in research and development, along with focused efforts to accelerate growth in key emerging markets and the companion animal segment, Elanco is projected to deliver double-digit annual income growth over the next five years.

Elanco is seen as providing both diversification and growth potential to the operations of Eli Lilly and Company, a leading global pharmaceutical corporation which Elanco is a division of.

Elanco employs more than 2,300 people worldwide, with offices in more than 40 countries.